Vyepti

RSS

eptinezumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Vyepti is a medicine used to prevent migraine in adults who have migraines at least 4 days a month.

Vyepti contains the active substance eptinezumab.

This EPAR was last updated on 29/11/2022

Authorisation details

Product details
Name
Vyepti
Agency product number
EMEA/H/C/005287
Active substance
eptinezumab
International non-proprietary name (INN) or common name
eptinezumab
Therapeutic area (MeSH)
Migraine Disorders
Anatomical therapeutic chemical (ATC) code
N02CD
Publication details
Marketing-authorisation holder
H. Lundbeck A/S
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
24/01/2022
Contact address

Ottiliavej 9
DK-2500 Valby
Denmark

Product information

28/11/2022 Vyepti - EMEA/H/C/005287 - IB/0004

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Analgesics

Therapeutic indication

Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating